Background Sofosbuvir/ledipasvir (SOF/LDV) combination is very effective against HCV. However, it was until recently approved for use in end-stage renal disease (ESRD), and on haemodialysis. Furthermore, No much data available for SOF/LDV in compensated and decompensated cirrhosis. Aims To assess the effectiveness and side-effects of SOF/LDV in HCV patients with ESRD, on haemodialysis, and have no cirrhosis or have either compensated or decompensated cirrhosis. Methods Data of 21 HCV patients was collected and they were on haemodialysis and had different CTP and were assessed for HCV at end treatment after 12 weeks, and after 12 and 24 weeks of end treatment. Treatment consisted of 90g of SOF/ 400g of LDV once daily. Results The sample contained 16 males and 5 females with mean age of 40.9 years. Three patients had decompensated cirrhosis CTP B, and four chronic hepatitis with minor cirrhotic changes with CTP A. Full follow-up was for only 20 patients and they all had HCV resolved as one patient passed away. Other factors were assessed such as HCV genotypes, but they had the same results with no difference in symptoms development. Conclusion SOF/LDV combination is suggested to be effective even if the patient was on haemodialysis and had compensated, or decompensated cirrhosis without the need of dose adjustment or increase duration with no major complications in patients with HCV 1a, 1b, 4, and 5.

Objectives: To evaluate the efficacy of Sofosbuvir/ledipasvir (SOF/LDV) combination for hepatitis C virus (HCV) in patients on haemodialysis and compensated liver cirrhosis as it was until recently approved by the FDA.Design: Retrospective study on patients who were on haemodialysis and used SOF/LDV for HCV.Setting: In one secondary health care facility (a hospital).Interventions: Treatment consisted of 90g of SOF/ 400g of LDV once daily. Patients were assessed for HCV at end treatment after 12 weeks and after 24 weeks for patients who had compensated cirrhosis with other follow-up for symptoms assessment.Results: The sample contained 16 males and 5 females with mean age of 40.9 years. Nineteen patients had no cirrhosis of the liver and the other two had clinical and radiological cirrhosis and had Child–Turcotte–Pugh (CTP) type B. Full follow-up was for only 20 patients and they all had HCV resolved as one patient passed away. Other factors were assessed such as HCV genotypes, but they had the same results with no difference in symptoms development (P>0.05).Conclusion: SOF/LDV combination is suggested to be effective when the patient is on haemodialysis and had compensated cirrhosis and CTP type B without the need of dose adjustment or increase duration with no major complications in patients with HCV 1a, 1b, 4, and 5.

Background Hepatitis C virus (HCV) infection is a high prevalent disease. Sofosbuvir/ledipasvir (SOF/LDV) can successfully treat HCV and it was until recently that SOF/LDV was approved by the FDA in haemodialysis patients, but not in patients with liver cirrhosis. This study reports patients on haemodialysis and compensated liver cirrhosis who used this regiment. This is a retrospective study on patients who were on haemodialysis and used SOF/LDV for HCV treatment in one secondary health care facility (a hospital). Treatment consisted of 400g SOF and of 90g LDV once daily. Patients were assessed for HCV RNA at the end of treatment after 12 weeks and after 24 weeks for patients. New symptoms were also assessed. Results Our sample contained 16 males and 5 females with a mean age of 40.9 years. Nineteen patients had no cirrhosis of the liver, and the other two had clinical and radiological cirrhosis and had Child–Turcotte–Pugh (CTP) type B. Full follow-up was for only 20 patients and they all had HCV resolved as one patient had died from a stroke. Other factors were assessed such as HCV genotypes, but treatment had the same results with no difference in symptoms development (p>0.05). Twelve patients had HCV genotype 1, eight patients had HCV genotype 4, and one patient had HCV genotype 5. Conclusion Despite the small sample size, SOF/LDV combination is suggested to be effective in patients on haemodialysis and who had compensated cirrhosis and CTP type B without the need of dose adjustment or increase duration of treatment, and there were no major complications overall.